CytomX Therapeutics Inc.

NASDAQ: CTMX · Real-Time Price · USD
1.93
0.17 (9.66%)
At close: Aug 15, 2025, 3:59 PM
1.93
0.26%
After-hours: Aug 15, 2025, 05:23 PM EDT

CytomX Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
50.92M 38.09M 33.43M 25.11M 41.46M 26.61M 26.38M 24.72M 23.5M 946K 16.91M 18.16M 17.14M 19.73M 17.59M 16.29M 15.97M
Cost of Revenue
n/a n/a n/a n/a n/a 486K 1.43M 1.53M 1.5M 1.49M 1.49M 1.45M n/a 1.48M n/a n/a n/a
Gross Profit
50.92M 38.09M 33.43M 25.11M 41.46M 26.12M 24.96M 23.19M 22M -543K 15.43M 16.71M 17.14M 18.24M 17.59M 16.29M 15.97M
Operating Income
22.62M 17.68M 4.11M -8.45M 11.66M -606K 3.12M -3.35M -5.65M -28.68M -23.94M -24.74M -23.97M -26.31M -22.64M -19.2M -15.63M
Interest Income
955K 1.28M 1.69M 1.97M 2.19M 2.5M 2.7M 2.31M 2.33M 732K 616K 262K 68K 73K 70K 44K 68K
Pretax Income
23.59M 18.94M 5.8M -6.48M 13.84M 1.91M 5.82M -1.09M -3.31M -27.95M -23.3M -24.18M -23.89M -26.23M -22.58M -19.24M -15.55M
Net Income
23.52M 18.88M 5.74M -6.53M 13.79M 837K 2.99M -1.09M -969K -26.58M -22.65M -23.63M -23.8M -26.23M -22.58M -19.24M -15.55M
Selling & General & Admin
9.43M 5.62M 7.95M 8.39M 7.75M 7.83M 6.81M 7.4M 7.98M 10.07M 10.49M 11.75M 10.54M 9.46M 11.09M 9.39M 9.23M
Research & Development
18.87M 14.79M 21.37M 25.17M 22.05M 18.94M 16.45M 20.67M 21.18M 19.56M 30.37M 31.16M 30.56M 36.58M 29.14M 26.1M 22.37M
Other Expenses
n/a n/a n/a n/a n/a n/a -7K -47K 15K 1K 30K 296K 13K 7K -13K -82K 5K
Operating Expenses
28.3M 20.41M 29.32M 33.57M 29.81M 27.21M 23.26M 28.07M 29.15M 29.63M 40.86M 42.91M 41.1M 46.03M 40.23M 35.49M 31.6M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
28.3M 20.41M 29.32M 33.57M 29.81M 27.21M 23.26M 28.07M 29.15M 29.63M 40.86M 42.91M 41.1M 46.03M 40.23M 35.49M 31.6M
Income Tax Expense
62K 62K 61K 51K 49K 1.07M 2.82M n/a -2.34M -1.37M -646K -558K -81K -73K -70K -44K -68K
Shares Outstanding (Basic)
87.12M 80.1M 85.09M 84.88M 82.03M 67.31M 80.73M 66.54M 66.25M 66.23M 65.91M 65.54M 65.39M 65.21M 64.53M 65.06M 60.97M
Shares Outstanding (Diluted)
87.15M 80.1M 85.2M 84.88M 82.63M 67.31M 80.99M 66.54M 66.25M 66.23M 65.91M 65.54M 65.39M 65.21M 65.21M 65.06M 60.97M
EPS (Basic)
0.27 0.22 0.07 -0.08 0.17 0.01 0.04 -0.02 -0.01 -0.4 -0.34 -0.36 -0.36 -0.4 -0.35 -0.3 -0.26
EPS (Diluted)
0.27 0.22 0.07 -0.08 0.17 0.01 0.04 -0.02 -0.01 -0.4 -0.34 -0.36 -0.36 -0.4 -0.35 -0.3 -0.26
EBITDA
23.01M 18.09M 4.54M -7.99M 12.12M -120K 3.61M -2.74M -5.06M -32.96M -29.09M -29.44M -31.46M -24.75M -21.96M -18.53M -14.95M
EBIT
22.62M 17.68M 4.11M -8.45M 11.66M -606K 3.12M -3.35M -5.65M -28.68M -29.71M -30.05M -32.06M -26.31M -22.64M -19.2M -15.63M
Depreciation & Amortization
385K 413K 429K 459K 467K 486K 484K 1.53M 1.5M 1.49M 1.49M 1.45M 1.43M 1.48M 1.47M 1.45M 1.43M